Annexon Inc. Overview
Annexon Inc., operating under the name Annexon Biosciences, is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company focuses on developing innovative therapies for autoimmune and neurodegenerative diseases affecting the body, eyes, and brain. Annexon Biosciences provides healthcare services to patients in California. The company is publicly traded on the Nasdaq stock exchange and more information can be found on their website, www.annexonbio.com .
Recent Developments
As of the latest update on May 16, 2025, Annexon has been relatively quiet in terms of public announcements. The company disclosed inducement grants to new employees, adhering to Nasdaq’s listing rules. This move is typical for publicly traded companies looking to attract and retain talent.
Market Performance
Annexon’s stock has experienced significant volatility over the past year. The 52-week high was recorded at $7.85 USD on October 17, 2024, while the 52-week low was $1.285 USD on April 9, 2025. As of May 15, 2025, the stock closed at $2.01 USD, indicating a substantial decline from its peak.
The company’s market valuation metrics include a price-to-earnings ratio of -1.57 and a book ratio of 0.81457. These figures suggest a complex valuation scenario, reflecting the challenges and uncertainties often faced by clinical-stage biopharmaceutical companies.
Financial Snapshot
- Market Cap: $198,580,000 USD
- Close Price (2025-05-15): $2.01 USD
- 52 Weeks High (2024-10-17): $7.85 USD
- 52 Weeks Low (2025-04-09): $1.285 USD
- Price-to-Earnings Ratio: -1.57
- Book Ratio: 0.81457
Annexon Inc. continues to focus on its mission to develop novel therapies for challenging medical conditions, despite the fluctuations in its stock performance.